Mendus (IMMU.ST)

Executive Summary

Mendus is a Swedish biopharmaceutical company founded in 2001, specializing in cancer immunotherapies based on dendritic cell biology. The company's approach aims to stimulate the body's active immunity against residual cancer cells, focusing on preventing tumor recurrence and improving long-term survival while maintaining quality of life. Its pipeline targets acute myeloid leukemia (AML), ovarian cancer, and various solid tumors. With a market capitalization of approximately $336 million and shares traded on Nasdaq Stockholm under the ticker IMMU.ST, Mendus is positioned as a small-cap biotech with significant potential in the immunotherapy space. The company has yet to commercialize a product but has advanced its lead candidates into clinical development, leveraging its proprietary dendritic cell platform.

Upcoming Catalysts (preview)

• Q4 2026Phase II data readout for lead DC vaccine in AML45% success
• Q3 2026Regulatory update or FDA interaction for ovarian cancer program60% success
• TBDPotential partnership or licensing deal for solid tumor program35% success